drugset / Trial / NCT02066909
A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese Volunteers
RandomizedParallel-groupDouble-blindBasic science
Summary
This study is designed to evaluate the safety and plasma concentrations of PF-06649751 in healthy volunteers following one or two times daily oral dosing of PF-06649751 for 14 days (Cohorts 1 - 4), 21 days (Cohort 5), or 28 days (Cohorts 6 - 8). Cohort 9 will dose Japanese healthy volunteers in a manner identical to Cohort 4 and is intended to bridge the safety/tolerability and PK data from the Western and Japanese populations.
Timeline
- Start
- 2014-02
- Primary completion
- 2015-04
- Completion
- 2015-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tavapadon | Small molecule | 0.15 mg | Oral |
| Subject | Tavapadon | Small molecule | 0.5 mg | Oral |
| Subject | Tavapadon | Small molecule | 1.5 mg | Oral |
| Subject | Tavapadon | Small molecule | 3 mg | Oral |
| Subject | Tavapadon | Small molecule | 5 mg | Oral |
| Subject | Tavapadon | Small molecule | 8 mg | Oral |
Indications
No indication recorded.